Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA NASDAQ:ETHZ NASDAQ:GLTO NASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.43+0.4%$2.28$1.55▼$5.00$17.11M0.1711,493 shs2,458 shsETHZFlag Ship Acquisition$2.44$0.00$0.66▼$17.75$14.74M0.374.64 million shs11.65 million shsGLTOGalecto$2.58-16.5%$3.40$2.01▼$14.82$3.41M1.35125,180 shs359,352 shsMTEXMannatech$9.12-2.7%$8.65$7.05▼$16.49$17.32M0.839,319 shs7,371 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech-2.97%+2.54%+14.15%+27.37%-44.62%ETHZFlag Ship Acquisition+5.63%-13.17%+243,999,900.00%+243,999,900.00%+243,999,900.00%GLTOGalecto+3.87%-2.71%-8.58%-8.04%-72.31%MTEXMannatech-2.09%+1.75%+15.68%-11.44%+24.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.43+0.4%$2.28$1.55▼$5.00$17.11M0.1711,493 shs2,458 shsETHZFlag Ship Acquisition$2.44$0.00$0.66▼$17.75$14.74M0.374.64 million shs11.65 million shsGLTOGalecto$2.58-16.5%$3.40$2.01▼$14.82$3.41M1.35125,180 shs359,352 shsMTEXMannatech$9.12-2.7%$8.65$7.05▼$16.49$17.32M0.839,319 shs7,371 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech-2.97%+2.54%+14.15%+27.37%-44.62%ETHZFlag Ship Acquisition+5.63%-13.17%+243,999,900.00%+243,999,900.00%+243,999,900.00%GLTOGalecto+3.87%-2.71%-8.58%-8.04%-72.31%MTEXMannatech-2.09%+1.75%+15.68%-11.44%+24.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 4.00Strong Buy$5.00105.76% UpsideETHZFlag Ship Acquisition 0.00N/AN/AN/AGLTOGalecto 3.00Buy$10.00287.60% UpsideMTEXMannatech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GLTO, MTEX, EDSA, and ETHZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AETHZFlag Ship AcquisitionN/AN/AN/AN/A$2.91 per shareN/AGLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AMTEXMannatech$117.87M0.15$2.03 per share4.48$4.57 per share1.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.32N/AN/AN/AN/A-162.95%-60.33%N/AETHZFlag Ship Acquisition-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%N/AGLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%11/7/2025 (Estimated)MTEXMannatech$2.49M-$2.04N/A∞N/A-3.46%-48.60%-10.70%11/10/2025 (Estimated)Latest GLTO, MTEX, EDSA, and ETHZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MTEXMannatechN/A-$2.27N/A-$2.27N/A$25.68 million8/8/2025Q3 2025EDSAEdesa Biotech-$0.26-$0.25+$0.01-$0.25N/AN/A8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AMTEXMannatechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A18.9618.96ETHZFlag Ship AcquisitionN/A0.580.58GLTOGalectoN/A4.964.96MTEXMannatech0.581.110.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%ETHZFlag Ship Acquisition4.07%GLTOGalecto14.20%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%ETHZFlag Ship Acquisition38.20%GLTOGalecto10.80%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.04 million5.45 millionNot OptionableETHZFlag Ship Acquisition76.04 million3.73 millionN/AGLTOGalecto401.32 million1.18 millionOptionableMTEXMannatech2501.90 million1.11 millionNot OptionableGLTO, MTEX, EDSA, and ETHZ HeadlinesRecent News About These CompaniesMannatech (NASDAQ:MTEX) Stock Crosses Below 200 Day Moving Average - Time to Sell?September 3, 2025 | americanbankingnews.comMannatech trading halted, volatility trading pauseAugust 14, 2025 | msn.comMannatech Reports Financial Results for Second Quarter 2025August 12, 2025 | businesswire.comMannatech, Incorporated (MTEX) - Yahoo FinanceJuly 24, 2025 | finance.yahoo.comMannatech names Peter Griscom as new chief operating officerJune 27, 2025 | investing.comMannatech Announces Promotion of Peter Griscom to Chief Operating Officer - MorningstarJune 27, 2025 | morningstar.comMMannatech appoints Peter Griscom COOJune 26, 2025 | msn.comMannatech Announces Promotion of Peter Griscom to Chief Operating OfficerJune 26, 2025 | businesswire.comMannatech Announces Results of Annual Shareholders’ MeetingJune 5, 2025 | finance.yahoo.comMannatech Announces Results of Annual Shareholders' MeetingJune 5, 2025 | businesswire.comMannatech Premieres Powerful New Documentary on Marathon Legend Steve EdwardsMay 21, 2025 | businesswire.comMannatech Reports Financial Results for First Quarter 2025May 13, 2025 | businesswire.comAstronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancementsApril 14, 2025 | msn.comMannatech Reports Fourth Quarter 2024 Financial ResultsMarch 26, 2025 | businesswire.comMannatech Stock Soars to 52-Week High, Hits $16 MarkJanuary 30, 2025 | msn.comMannatech names Robert Toth vice chairman of the boardNovember 27, 2024 | markets.businessinsider.comMannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of DirectorsNovember 26, 2024 | businesswire.comMannatech Inc. Q3 Earnings SummaryNovember 13, 2024 | markets.businessinsider.comMannatech Reports Financial Results for Third Quarter 2024November 12, 2024 | businesswire.comTrading (MTEX) With Integrated Risk ControlsOctober 17, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLTO, MTEX, EDSA, and ETHZ Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.43 +0.01 (+0.41%) Closing price 03:59 PM EasternExtended Trading$2.42 -0.01 (-0.41%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Flag Ship Acquisition NASDAQ:ETHZ$2.44 0.00 (0.00%) As of 04:00 PM Eastern1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Galecto NASDAQ:GLTO$2.58 -0.51 (-16.50%) Closing price 04:00 PM EasternExtended Trading$2.56 -0.02 (-0.78%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Mannatech NASDAQ:MTEX$9.12 -0.26 (-2.72%) Closing price 03:58 PM EasternExtended Trading$8.54 -0.58 (-6.31%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
